,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,5217 Winnebago Lane,Austin,TX,78744,United States,512 386 2900,512 386 5505,https://www.xbiotech.com,Biotechnology,Healthcare,"XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.",84,"{'maxAge': 1, 'name': 'Mr. John  Simard', 'age': 60, 'title': 'Founder, Pres, CEO & Chairman', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 4670934, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,9,5,8,1693526400,1672444800,86400,4,4.34,4.3,4.3,4.3,4.34,4.3,4.3,4.3,1626307200,0.0,1.230636,200,200,0,0,0,4.26,4.38,30000,30000,130873512,2.72,5.85,66.09773,4.5784,3.88196,0.0,0.0,EUR,-73897432,0.0,19800562,30435700,0.35158002,0.12038,7.526,0.57135266,1672444800,1703980800,1688083200,-28419000,-0.86,-37.322,2.246,FRA,EQUITY,4XB.F,4XB.F,XBIOTECH INC.,XBiotech Inc.,1429250400,Europe/Berlin,CEST,7200000,4.3,2.0,buy,204771008,6.728,-32898000,0,46.869,47.081,1980000,0.065,-0.0871,-0.11723,3359000,-12116625,-18119000,0.88333,0.0,-17.65303,USD,
1,5217 Winnebago Lane,Austin,TX,78744,United States,512 386 2900,512 386 5505,https://www.xbiotech.com,Biotechnology,Healthcare,"XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.",84,"{'maxAge': 1, 'name': 'Dr. Sushma  Shivaswamy Ph.D.', 'age': 44, 'title': 'Chief Scientific Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 381240, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,9,5,8,1693526400,1672444800,86400,4,4.34,4.3,4.3,4.3,4.34,4.3,4.3,4.3,1626307200,0.0,1.230636,200,200,0,0,0,4.26,4.38,30000,30000,130873512,2.72,5.85,66.09773,4.5784,3.88196,0.0,0.0,EUR,-73897432,0.0,19800562,30435700,0.35158002,0.12038,7.526,0.57135266,1672444800,1703980800,1688083200,-28419000,-0.86,-37.322,2.246,FRA,EQUITY,4XB.F,4XB.F,XBIOTECH INC.,XBiotech Inc.,1429250400,Europe/Berlin,CEST,7200000,4.3,2.0,buy,204771008,6.728,-32898000,0,46.869,47.081,1980000,0.065,-0.0871,-0.11723,3359000,-12116625,-18119000,0.88333,0.0,-17.65303,USD,
2,5217 Winnebago Lane,Austin,TX,78744,United States,512 386 2900,512 386 5505,https://www.xbiotech.com,Biotechnology,Healthcare,"XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.",84,"{'maxAge': 1, 'name': 'Ms. Angela  Hu', 'age': 38, 'title': 'Director of Fin., Principal Financial & Accounting Officer and Financial Controller', 'yearBorn': 1984, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,9,5,8,1693526400,1672444800,86400,4,4.34,4.3,4.3,4.3,4.34,4.3,4.3,4.3,1626307200,0.0,1.230636,200,200,0,0,0,4.26,4.38,30000,30000,130873512,2.72,5.85,66.09773,4.5784,3.88196,0.0,0.0,EUR,-73897432,0.0,19800562,30435700,0.35158002,0.12038,7.526,0.57135266,1672444800,1703980800,1688083200,-28419000,-0.86,-37.322,2.246,FRA,EQUITY,4XB.F,4XB.F,XBIOTECH INC.,XBiotech Inc.,1429250400,Europe/Berlin,CEST,7200000,4.3,2.0,buy,204771008,6.728,-32898000,0,46.869,47.081,1980000,0.065,-0.0871,-0.11723,3359000,-12116625,-18119000,0.88333,0.0,-17.65303,USD,
